The top 5 vaccines by 2020

Pfizer's ($PFE) Prevnar 13 currently dominates the list of the world's best-selling vaccines--and that won't be changing anytime soon, according to a new report from EvaluatePharma. In fact, it's expected to widen its lead, with sales growing more than 61% over the next 5+ years; by 2020, it will be generating nearly $4 billion more than runner up Pentacel from Sanofi ($SNY), EP predicts.

As far as the rest of the list, however, EP anticipates a bit of shuffling. Merck's ($MRK) Gardasil, last year's No. 2 seller, will slide into third place to make room for Pentacel. And GlaxoSmithKline's ($GSK) Pediarix will inch up into fifth, knocking Merck's varicella jab Varivax out of the top 5.

Take a look at the specifics and check out how the 2020 forecasts stack up to the top 10 best-selling vaccines of 2013. You can also peruse the rest of EP's report by downloading it here. Questions? Comments? Let us know. -- Carly Helfand (email | Twitter)

The top 5 vaccines by 2020
Vaccine & Company
Use
2013 Sales (billions)
2020 Sales (billions)
CAGR 2013-20

Pneumococcal infection
$3.76
$6.08
7%

Diphtheria, pertussis/whooping cough; tetanus; polio; Haemophilus influenzae type B
$1.53
$2.34
6%

Human papillomavirus (HPV)
$1.83
$2.06
2%

Influenza
$1.23
$1.82
6%

Diphtheria; tetanus; pertussis/whooping cough; hepatitis B; polio
$1.35
$1.72
4%
Courtesy of EvaluatePharma

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

Find out how PDA can help you succeed with custom solutions and training for your employees – at your facility, our facility, or virtually.

Iowa State University is working on a room-temp-stable nasal spray vaccine for COVID-19, and it recently tapped device maker Zeteo for support.

Pfizer's shot will go before an FDA expert panel on Dec. 10, with Moderna's review pegged for the 17th, Warp Speed chief Moncef Slaoui, Ph.D., said.